Screener
Gilead Sciences GILD Non-Controlling Interests
Non-Controlling Interests at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:MinorityInterest.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions, except per share amounts) | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Common stock, par value $0.001 per share; 5,600 shares authorized; 1,241 shares issued and outstanding | 1 | 1 |
| Additional paid-in capital | 9,532 | 8,932 |
| Accumulated other comprehensive income | 95 | 39 |
| Retained earnings | 2,200 | 13,730 |
| Total Gilead stockholders’ equity | 11,829 | 22,703 |
| Noncontrolling interest | (84) | (84) |
| Total stockholders’ equity | 11,744 | 22,618 |
| Total liabilities and stockholders’ equity | $49,362 | $59,023 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's non-controlling interests?
- Gilead Sciences (GILD) reported non-controlling interests of -$84M in Q2 2026.
- How has Gilead Sciences's non-controlling interests changed year-over-year?
- Gilead Sciences's non-controlling interests decreased by 0.0% year-over-year, from -$84M to -$84M.
- What is the long-term trend for Gilead Sciences's non-controlling interests?
- Over 5 years (2020 to 2025), Gilead Sciences's non-controlling interests has grown at a 34.6% compound annual growth rate (CAGR), from $19M to -$84M.
- What does non-controlling interests mean?
- Equity attributable to minority shareholders in subsidiaries not fully owned by the parent — their proportional claim on subsidiary net assets.
Ask your AI about Gilead Sciences's non-controlling interests.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude